Phathom Pharmaceuticals, Inc. Non-operating Interest Expenses

Non-operating Interest Expenses of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending September 29, 2021 was $8 Thousand (a -38.46% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses decreased by -50.0%
  • Annual Non-operating Interest Expenses for 2020 was $1.09 Million (a 0.18% increase from previous year)
  • Annual Non-operating Interest Expenses for 2019 was $1.09 Million (a 8276.92% increase from previous year)
  • Twelve month Non-operating Interest Expenses ending September 29, 2021 was $51 Thousand (a -12.07% decrease compared to previous quarter)
  • Twelve month trailing Non-operating Interest Expenses decreased by -97.49% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$51 Thousand $58 Thousand $1.31 Million $2.03 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of Phathom Pharmaceuticals, Inc.

Most recent Non-operating Interest Expensesof PHAT including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.01 $0.01 $0.01
2020 $0.02 $0.02 $1.26 $0.74 $1.09
2019 $1.04 $1.99 $1.14 $0.01 $1.09
2018 $0.0 $0.01

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.